Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE DATED JULY 12, 2021 - Monopar Therapeutics | mnpr_ex991.htm |
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d)
of The Securities
Exchange Act of 1934
Date of Report (Date of earliest
event reported): July 12, 2021
MONOPAR
THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-39070
|
|
32-0463781
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
1000 Skokie Blvd., Suite 350, Wilmette,
IL 60091
|
|
60091
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
(847)
388-0349
Registrant’s telephone number,
including area code
N/A
(Former name or former address, if
changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
Title of each
class
|
|
Trading
Symbol(s)
|
|
Name of each
exchange on which registered
|
Common Stock,
$0.001 par value
|
|
MNPR
|
|
The Nasdaq Stock
Market LLC
(Nasdaq Capital
Market)
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions:
☐ Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of
the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of
this chapter).
Emerging growth company ☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act. ☒
On July
12, 2021, Monopar Therapeutics Inc. issued a press release
announcing the appointment
of Octávio Costa, MD, as Chief Medical
Officer. In this role, Dr. Costa will oversee global clinical
development and regulatory affairs, and will provide strategic
direction for Monopar’s pipeline.
The press
release is furnished as Exhibit 99.1 to this report and
incorporated herein by reference.
Item 9.01 Financial Statements and
Exhibits
Exhibit No.
|
Description
|
Press Release Dated July 12,
2021
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Monopar Therapeutics Inc.
|
|
|
|
|
|
|
Date: July 12, 2021
|
By:
|
/s/ Kim R. Tsuchimoto
|
|
|
|
Name: Kim R. Tsuchimoto
|
|
|
|
Title: Chief Financial Officer, Secretary and
Treasurer
|
|